Single Use Bioreactors Market Market Analysis: Growth Drivers and Opportunities
The global single use bioreactors market
is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in
2021, at a CAGR of 21.1% during the forecast period. The growth of this
market is mainly driven by the increasing adoption of SUBs among small
companies and startups, reduced automation complexity, ease in the
cultivation of marine organisms, reduced energy and water consumption,
the growing biologics market, technological advancements in SUBs, and
increasing Biopharmaceutical R&D.
The prominent players
operating in the single use bioreactors market are Sartorius Stedim
Biotech (France), Thermo Fisher Scientific (US), Danaher Corporation
(US), and Merck KGaA (Germany).
Sartorius Stedim Biotech held the
leading position in the single-use bioreactors market in 2019.
Sartorius focuses on strengthening its position in the market by
adopting organic and inorganic strategies such as product launches and
expansions. During the past three years, Sartorius Stedim Biotech
launched SUB systems such as BIOSTAT STR Generation 3 Single-Use
Bioreactor, BIOSTAT RM TX Single-Use Bioreactor, and BIOSTAT STR. In
2019, Sartorius agreed to acquire parts of Danaher’s Life Science
portfolio, which is complementary to the portfolio of Sartorius’s
laboratory and bioprocess business. This transaction was completed in
the first quarter of 2020.
Danaher Corporation is the
second-largest player operating in the single-use bioreactors market
through its subsidiary, Pall Corporation. Pall Corporation offers a wide
range of single-use bioreactors, 2D and 3D biocontainer system
assemblies, single-use consumables, and accessories. In March 2020,
Danaher completed the Biopharma business of General Electric Company’s
Life Sciences division and rebranded it as Cytiva. With this
acquisition, Danaher enhanced its market position to become a leading
player in the single-use bioreactors market. To further increase its
share in the single-use bioreactors market, the company focuses on
inorganic strategies. The company entered into several agreements and
partnerships from 2017 to 2020, with biopharmaceutical manufacturers and
institutes such as Freeline (UK), Aetos Biologics (Italy), and New
Jersey Institute of Technology (NJIT, US) to offer cost-effective
biomanufacturing solutions.
Drivers: Reduced automation complexity
SUBs
increase the quality of the end product by reducing automation
complexity. In the case of stainless-steel bioreactors, the complexity
of the bioreactor increases with the number of in and out points. In
stainless steel bioreactors, many points need to be checked to maintain
valve control or monitoring temperature. On the other hand, owing to the
improved design, SUBs have fewer pipes, valves, and instruments, thus
resulting in the need for less monitoring for valve control or
temperature. Reduced design complexities in SUBs also eliminate the need
for surface cleaning, eliminating contamination and cross-contamination
of cultures. Contamination is a major problem while using traditional
bioreactors. As a result, the overall manufacturing process with SUBs is
simpler than traditional bioreactors.
Opportunities: Emerging markets
The
growing presence of global and local pharmaceutical &
biopharmaceutical companies in these countries is a major factor driving
the demand of the market. For instance, In April 2020, India’s leading
drug companies, including Lupin and Dr. Reddy’s, have had their
pharmaceutical manufacturing facilities cleared with US Food and Drug
Administration (USFDA) inspection. In 2020, Serum Institute and Bharat
Biotech had expanded their COVID-19 vaccine manufacturing capacity and
installed SU bioreactors. With the increase in pharmaceutical &
biopharmaceutical manufacturing, government authorities in these
countries focus on good manufacturing practices and validated laboratory
procedures. Implementing regulatory measures to prohibit the import
& supply of drugs (that are contaminated or impure after
bioprocessing) is expected to increase the demand for cost-effective
single-use systems in these countries.
Related Links
https://www.marketsandmarkets.com/Market-Reports/single-use-bioreactor-market-49113750.html
https://www.marketsandmarkets.com/PressReleases/single-use-bioreactor.asp
https://www.marketsandmarkets.com/ResearchInsight/single-use-bioreactor-market.asp
Comments
Post a Comment